Ann: PharmAust to Evaluate Monepantel on COVID-19, page-149

So far so good. No news that the trial with COVID19 has failed.... Our "No News is Good News" applies here too.

I am figuring that the trial would be conducted hard and fast given the circumstance. I also reflect on a couple of points:
1 - I would think the virus needs to be knocked for 6 (cricket ref) in a petri dish very quickly to be an effective treatment worthy of pursuit.
2 - PharmAust leadership do not like putting out deadlines, but they have here - May 2020. I did double check to see if they added the year .
3 - PharmAust are paying a nominal fee and time is money so I am guessing it is not going to take much time to get a preliminary indication of probability.

So, I we might know earlier rather than later BUT ........... May is a long month and we are still waiting for a meaningful trend elsewhere, even though none of us know the definition of meaningful. It will be like Christmas when news finally comes (i hope).

I was also thinking about the correlation between cancer fight and COVID fight. One would probably expect doses to be different depending on the problem to solve. Maybe even formula variations given virus fight is very short and very sharp, Cancer is short but then maintained. Question on COVID19, would you also supply the doses to those at very high risk (direct contact with a known case or in a nursing home where a case has presented)? While clearly not a vaccine, not sure if taking dosages could have a preventative of high severity effect should infection occur soon after.


Still just adreamer.